Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory Evaluation of Host Biomarkers That Predict the Vaccine Virus Replication and Immunogenicity of Seasonal and Pandemic Formulations of Live Attenuated Influenza A Virus Vaccines Based on the A/Ann Arbor/6/60 ca Master Donor Virus (MDV)

Trial Profile

Exploratory Evaluation of Host Biomarkers That Predict the Vaccine Virus Replication and Immunogenicity of Seasonal and Pandemic Formulations of Live Attenuated Influenza A Virus Vaccines Based on the A/Ann Arbor/6/60 ca Master Donor Virus (MDV)

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Influenza A virus vaccine H2N3 (Primary) ; Influenza A virus vaccine-H9N2 (Primary) ; Influenza virus vaccine live (Primary)
  • Indications Influenza virus infections
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Dec 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 03 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top